[go: up one dir, main page]

WO2006133549A1 - Supplément alimentaire pour causer perte rapide de poids, contrôle de l’appétit, gestion du stress, facilitation de la relaxation, lutte contre la fatigue et aide au bien-être mental - Google Patents

Supplément alimentaire pour causer perte rapide de poids, contrôle de l’appétit, gestion du stress, facilitation de la relaxation, lutte contre la fatigue et aide au bien-être mental Download PDF

Info

Publication number
WO2006133549A1
WO2006133549A1 PCT/CA2006/000964 CA2006000964W WO2006133549A1 WO 2006133549 A1 WO2006133549 A1 WO 2006133549A1 CA 2006000964 W CA2006000964 W CA 2006000964W WO 2006133549 A1 WO2006133549 A1 WO 2006133549A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
diet supplement
diet
per serving
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2006/000964
Other languages
English (en)
Inventor
Marvin A. Heuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smartburn Formulations Ltd
Original Assignee
Smartburn Formulations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartburn Formulations Ltd filed Critical Smartburn Formulations Ltd
Priority to EP06752797A priority Critical patent/EP1893225A4/fr
Priority to AU2006257660A priority patent/AU2006257660A1/en
Publication of WO2006133549A1 publication Critical patent/WO2006133549A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being.
  • the diet supplement is provided in a caplet form consumable several times per day, for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being throughout the day.
  • the present invention relates to a method of promoting same by consuming the diet supplement.
  • the present invention relates to a method of manufacturing the diet supplement.
  • the present invention provides for a diet supplement causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being.
  • the diet supplement may include one or more of the Calcium and Potassium double salt of Garcinia Cambogia Extract standardized to about 60% Hydroxycitric Acid, Gymnema Sylvestre Leaf Extract, Rhodiola Rosea Root Extract, Theanine (gamma-glutamylethylamide), Astaxanthin, Chromium Polynicotinate, Hoodia Gordonii (e.g., an extract that does not contain any extract from the root of the plant), N-olyl-phosphatidyl ethanolamine (NOPE)/EGCG blend, Vinpocetine, Russian Tarragon Extract (Artemisia dracunculus L.
  • NOPE N-olyl-phosphatidyl ethanolamine
  • the present invention may provide a diet supplement comprising an extract of Hoodia i Gordonii and Vinpocetine, wherein the Hoodia Gordonii extract does not contain any extract from the roots of the plant.
  • the diet supplement may also include any one or more of an extract of Rhodiola Rosea, Theanine, an Astaxanthin extract of Algae, Chromium Polynicotinate, a blend of N-olyl-phosphatidyl ethanolamine/EGCG Blend, an extract of Russian Tarragon, N-acetyl tyrosine, an extract of Withania Somnifera, an extract of Gymnema Sylvestre, and the Calcium and Potassium double salt of Garcinia Cambogia Extract supplying about 60% Hydroxycitric Acid.
  • an extract of Rhodiola Rosea Theanine
  • an Astaxanthin extract of Algae Chromium Polynicotinate
  • a blend of N-olyl-phosphatidyl ethanolamine/EGCG Blend a blend of N-olyl-phosphatidyl ethanolamine/EGCG Blend
  • an extract of Russian Tarragon N-acetyl tyrosine
  • an extract of Withania Somnifera an extract of Gymnem
  • the diet supplement is provided in a caplet form, which may be consumed several times per day.
  • the diet supplement comprises a two caplet serving; each serving suitable for being consumed three times daily, e.g., before each one of three daily meals.
  • the diet supplement may cause rapid weight loss, control appetite, manage stress, support relaxation, combat fatigue and support mental well-being for an extended period of time, e.g., all day.
  • the present invention also provides, by the consumption of the supplemental composition, a method for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, and supporting mental well-being.
  • the present invention may provide a method for controlling appetite and promoting rapid weight loss, comprising the step of administering to a human or animal a diet supplement that comprises an extract of Hoodia Gordonii, wherein the Hoodia Gordonii extract does not contain any extract from the roots of the plant, and may also comprise one or more of the Calcium and Potassium double salt of Garcinia Cambogia Extract supplying 60% Hydroxycitric Acid, Gymnema Sylvestre, Chromium Polynicotinate, N-olyl-phosphatidyl Ethanolamine/EGCG Blend, an extract of Russian Tarragon and Vinpocetine.
  • the method may include the step of administering the diet supplement to a human or animal at least once daily.
  • the present invention relates to a method of manufacturing a diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being.
  • a diet supplement comprising one or more of the Calcium and Potassium double salt of Garcinia Cambogia Extract standardized to about 60% Hydroxycitric Acid, Gymnema Sylvestre Leaf Extract, Rhodiola Rosea Root Extract, Theanine (gamma- glutamylethylamide), Astaxanthin, Chromium Polynicotinate, Hoodia Gordonii (e.g., an extract that does not contain any extract from the root of the plant), N-olyl- phosphatidyl ethanolamine (NOPE)/EGCG blend, Vinpocetine, Russian Tarragon Extract (Artemisia dracunculus L. plant), N-acetyl tyrosine and Withania Somnifera Root Extract.
  • Theanine gamma- glutamylethylamide
  • Astaxanthin Chromium Polynicotinate
  • Hoodia Gordonii e.g., an extract that does not contain any extract from the root of the plant
  • NOPE N-olyl-
  • the present invention may relate to a method of managing stress comprising the step of administering to a human or animal a diet supplement that comprises an extract of Rhodiola Rosea, Theanine, N-acetyl Tyrosine and an extract of Withania Somnifera Root.
  • the present invention may relate to a method of supporting relaxation comprising the step of administering to a human or animal a diet supplement that comprises Theanine and an extract of Russian Tarragon.
  • the present invention may relate to a method of supporting mental well-being comprising the step of administering to a human or animal a diet supplement that comprises an extract of Rhodiola Rosea, Theanine, Astaxanthin extract of Algae, Vinpocetine, N-acetyl Tyrosine and an extract of Withania Somnifera Root.
  • the present invention may relate to a method of ameliorating mental performance comprising the step of administering to a human or animal a diet supplement that comprises Vinpocetine, an extract of Rhodiola Rosea, and N-acetyl Tyrosine.
  • the present invention may relate to a method of regulating blood glucose levels comprising the step of administering to a human or animal a diet supplement that comprises an extract of Gymnema Sylvestre, Chromium Polynicotinate, and an extract of Russian Tarragon.
  • the present invention may relate to a method of supplying antioxidants to a human or animal comprising the step of administering to a human or animal a diet supplement that comprises an extract of Rhodiola Rosea, Theanine, an extract of Astaxanthin, N- olyl-phosphatidyl Ethanolamine/EGCG Blend, and an extract of Withania Somnifera Root.
  • the present invention is directed to a diet supplement for inducing rapid weight loss, controlling appetite, and managing stress, supporting relaxation, combating fatigue and supporting mental well-being.
  • Hoodia is a cactus which has been used traditionally to ease hunger discomfort and as such, is used as an appetite suppressant.
  • a suspected active compound isolated from Hoodia Root, termed P57 has been shown to reduce food intake in rats (MacLean DB, Luo LG. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res. 2004 Sep 10; 1020(1 -2):1 -11.). Furthermore, it was found that P57 countered the reduction in ATP normally expected from calorie restriction.
  • Phytopharm completed a double-blind, placebo-controlled trial comprised of a group of healthy yet overweight volunteers. Following two weeks of high doses of Hoodia, the treatment group showed a reduction in weight while being inactive, and further, their daily caloric intake was voluntarily reduced via appetite suppression by approximately 1000 calories.
  • the diet supplement may include Hoodia Gordonii (e.g., an extract that does not contain any extract from the root of the plant).
  • a serving of the diet supplement may include from about 1.0 mg to about 100 mg of Hoodia Gordonii (e.g., an extract that does not contain any extract from the root of the plant).
  • the preferred dosage, in a serving of said diet supplement comprises about 20 mg of Hoodia Gordonii (e.g., an extract that does not contain any extract from the root of the plant).
  • Vinpocetine is an extract of Vinca minor, or periwinkle plant, used traditionally to improve circulation. Vinpocetine has been shown to prevent brain cell damage by increasing blood flow in a rat model of forebrain ischemia (2-vessel occlusion and hypotension) wherein the ischemia was maintained for 10 minutes (Sauer D, Rischke R, Beck T, Rossberg C, Mennel HD, Bielenberg GW, Krieglstein J. Vinpocetine prevents ischemic cell damage in rat hippocampus. Life Sci. 1988; 43(21 ):1733-9).
  • Image analysis indicates that Vinpocetine can increase cerebral blood flow in stroke patients and thereby improving cerebral glucose uptake and metabolism in the brain (Szakall S, Boros I, Balkay L, Emri M, Fekete I, Kerenyi L, Lehel S, Marian T, Molnar T, Varga J, Galuska L, Tron L, Bereczki D 1 Csiba L, Gulyas B. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging.
  • Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur J Pharmacol. 1995 Feb 6;273(3):303-6.), which is thought to be involved in neuroprotection (Bonoczk P, Gulyas B, Adam-Vizi V, Nemes A, Karpati E, Kiss B, Kapas M, Szantay C, Koncz I 1 Zelles T, Vas A. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000 Oct; 53(3): 245-54.). The antioxidant activity of Vinpocetine may also contribute to protection of neural cells (Santos MS, Duarte Al, Moreira Pl, Oliveira CR.
  • Vinpocetine may also prevent the accumulation of calcium, phosphorus and aluminum in the central nervous system, which has been suggested to be involved in atherosclerosis (Yasui M, Yano I, Ota K, Oshima A. Calcium, phosphorus and aluminum concentrations in the central nervous system, liver and kidney of rabbits with experimental atherosclerosis: preventive effects of vinpocetine on the deposition of these elements. J lnt Med Res. 1990 Mar-Apr; 18(2): 142-52. ).
  • Vinpocetine has been shown to be effective at treating a number of circulation-related disorders.
  • Vinpocetine was shown to effect significant improvement in elderly patients with chronic cerebral dysfunction (Balestreri R, Fontana L, Astengo F.
  • a single-blind randomized trial has demonstrated the feasibility of continued study of Vinpocetine to treat stroke patients (Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchervov DV.
  • Vinpocetine treatment in acute ischaemic stroke a pilot single-blind randomized clinical trial. Eur J Neurol. 2001 Jan; 8(1):81- 5.). Further to these studies, it was shown that cognitive performance improved in patients with mild to moderate pychosyndromes such as dementia (Hindmarch I, Fuchs HH, Erztechnik H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes, lnt Clin Psychopharmacol. 1991 spring;6(1 ):31-43.). An improvement in the memory of healthy women due to a three-day supplementation with Vinpocetine has also been documented (Subhan Z, Hindmarch I. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol. 1985;28(5):567-71.).
  • the diet supplement may include Vinpocetine.
  • a serving of the diet supplement may include from about 0.1 mg to about 10 mg of Vinpocetine.
  • the preferred dosage, in a serving of said diet supplement, comprises about 1 mg of Vinpocetine.
  • Theanine (gamma-glutamylethytamide)
  • Theanine is an amino acid found in green tea. It is however distinct from the polyphenols and Catechins that are typically associated with the beneficial effects of green tea. While Catechins are generally associated with antioxidant activity, Theanine is associated with anti-stress and Cortisol control. In hypertensive rats, Theanine has been shown to lower blood pressure (Yokogoshi H, Kato Y, Sagesaka YM, Takihara-Matsuura T, Kakuda T, Takeuchi N. Reduction effect of theanine on blood pressure and brain 5-hydroxyindoles in spontaneously hypertensive rats. Biosci Biotechnol Biochem.
  • Theanine possess neuroprotective effects in animal models of brain damage (Kakuda T, Yanase H, Utsunomiya K, Nozawa A, Unno T, Kataoka K. Protective effect of gamma-glutamylethylamide (Theanine) on ischemic delayed neuronal death in gerbils. Neurosci Lett. 2000 Aug 11 ;289(3): 189-92.) which is thought to be due to inhibiting the ligand binding to glutamate receptors (Kakuda T, Nozawa A, Sugimoto A, Niino H.
  • the diet supplement may include Theanine (gamma- glutamylethylamide).
  • a serving of the diet supplement may include from about 1.0 mg to about 100 mg of Theanine (gamma-glutamylethylamide).
  • the preferred dosage, in a serving of said diet supplement comprises about 52 mg of Theanine (gamma-glutamylethylamide).
  • Astaxanthin is a red carontenoid pigment occurring naturally in many living organisms. Studies utilizing animals indicate that Astaxanthin can confer antioxidant activity that can attenuate exercise-induced muscle damage (Aoi W, Naito Y, Sakuma K, Kurissa M, Tokuda H, Maoka T, Toyokuni S, Oka S, Yasuhara M, Yoshikawa T. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal. 2003 Feb;5(1):139-44.) F has anticancer activity (Jyonouchi H, Sun S, lijima K, Gross MD. Antitumor activity of astaxanthin and its mode of action. Nutr Cancer.
  • the diet supplement may include Astaxanthin.
  • a serving of the diet supplement may include from about 1 mg to about 100 mg of Astaxanthin.
  • the preferred dosage, in a serving of said diet supplement, comprises from about 5 mg of Astaxanthin.
  • Chromium is an essential trace mineral that is used to control blood sugar levels by aiding insulin binding, wherein it can aid in the control weight of reduction. Chromium, however, is poorly absorbed by the body and must therefore be combined with a more efficiently absorbed compound such as niacin (found in Polynicotinate). Chromium likely exerts its main function as a component of the glucose tolerance factor, which is involved in insulin sensitivity.
  • Chromium has been shown clinically to increase lean mass (Bahadori B, Wallner S, Schneider H, Wascher TC, Toplak H. Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet. Acta Med Austriaca. 1997;24(5):185-7.) and reduce body fat when combined with exercise (Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc. 1997 Aug;29(8):992-8.). Chromium has also been shown to increase HDL, ('good') cholesterol (Riales R, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. Am J Clin Nutr 1981 ;34:2670-8.).
  • the diet supplement may include Chromium Polynicotinate.
  • a serving of the diet supplement may include from about 0.01 mg to about 10 mg of Chromium Polynicotinate.
  • the preferred dosage, in a serving of said diet supplement comprises about 0.133 meg (0.000133 g) of Chromium Polynicotinate.
  • N-olyl-phosphatidyl ethanolamine (“NOPE”)/ EGCG blend NOPE is a naturally occurring lipid synthesized and released in the intestine.
  • NOPE neuropsychopharmacology. 2003 Jul;28(7):1311-6.
  • NOPE has been shown to lower body weight in obese rats (Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005 Jun;48(8):1147-53.).
  • PPAR-alpha peroxisome- proliferator-activated receptor-alpha
  • PPAR-alpha peroxisome- proliferator-activated receptor-alpha
  • GPCR G protein-coupled receptor
  • EGCG Epigallocatechin-3-gallate
  • EGCG is the most active Catechin polyphenol compound found in Green Tea.
  • EGCG has potent antioxidant activity and has been shown by laboratory tests to be greater than many well known and established antioxidants such as vitamin C and E (Pillai SP, Mitscher LA, Menon SR, Pillai CA, Shankel DM. Antimutagenic/antioxidant activity of green tea components and related compounds. J Environ Pathol Toxicol Oncol. 1999; 18(3): 147-58). Further to its antioxidant activity, EGCG was found to be effective at reducing food intake, body weight, cholesterol and triglycerides in both lean and obese rats (Kao YH, Hiipakka RA, Liao S.
  • Catechins are also known to inhibit catechol-O-methyl-transferase (COMT), an enzyme that degrades norepinephrine (Borchardt RT, Huber JA.
  • Catechins are also known to inhibit catechol-O-methyl-transferase (COMT), an enzyme that degrades norepinephrine (Borchardt RT, Huber JA.
  • norepinephrine inhibits degradation of intracellular cyclic AMP (cAMP), an important signaling molecule involved in many metabolic processes including thermogenesis.
  • cAMP cyclic AMP
  • EGCG has been shown to be an inhibitor of glutamate dehydrogenase, which regulates insulin secretion (Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos. 2003 May;31 (5):572-9.).
  • the diet supplement may include an N-olyl-phosphatidyl ethanolamine ("NOPE”)/ EGCG blend.
  • a serving of the diet supplement may include from about 0.1 mg to about 10 mg of N-olyl-phosphatidyl ethanolamine (NOPE)/EGCG blend.
  • the preferred dosage, in a serving of said diet supplement comprises about 1 mg of N-olyl-phosphatidyl ethanolamine (NOPE)/EGCG blend.
  • Russian Tarragon (Artemisia dracunculus) is a perennial herb widely used in cooking. Historically it has been used as a natural blood cleanser and as a treatment for headaches and dizziness. Current studies are examining the use of the ethanolic extract of Russian Tarragon called for the treatment of hyperglycemia associated with diabetes. The toxicology of this extract has been evaluated, and shown to be safe and non-toxic (Ribnicky DM, Poulev A, O'Neal J, Wnorowski G, Malek DE, Jager R, Raskin I. Toxicological evaluation of the ethanolic extract of Artemisia dracunculus L. for use as a dietary supplement and in functional foods. Food Chem Toxicol.
  • the diet supplement may include Russian Tarragon Extract (Artemisia dracunculus L. plant).
  • a serving of the diet supplement may include from about 0.1 mg to about 10 mg of Russian Tarragon Extract (Artemisia dracunculus L. plant).
  • the preferred dosage, in a serving of said diet supplement comprises about 1 mg of Russian Tarragon Extract (Artemisia dracunculus L. plant).
  • N-acetyl tyrosine is a stable form of the amino acid tyrosine.
  • Tyrosine is a nonessential amino acid, meaning that it can be synthesized by the body. Amino acids are the building blocks of protein. Tyrosine can also function as a neurotransmitter precursor and is converted into neuronal signaling molecules such as dopamine, norepinephrine, and epinephrine. It is known that increasing levels of neurotransmitter precursors in the brain stimulates further neurotransmitter production (Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacol Rev. 1980 Dec;32(4):315-35).
  • Tyrosine levels in the brain and the subsequent conversion into neurotransmitters has been shown to increase in response to increased dietary Tyrosine (Femstrom JD, Femstrom MH. Dietary effects on tyrosine availability and catecholamine synthesis in the central nervous system: possible relevance to the control of protein intake. Proc Nutr Soc. 1994 Jul;53(2):419-29.).
  • Tyrosine depletion in humans has been shown to have detrimental effects on mood (Leyton M, Young SN, Pihl RO, Etezadi S 1 Lauze C, Blier P, Baker GB, Benkelfat C. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology.
  • Tyrosine supplementation has be used to successfully improve mood and cognitive performance during periods of stress (Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull. 1989 Apr;22(4):759-62).
  • One study has demonstrated a reduction in blood pressure in addition to cognitive improvement (Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. Brain Res Bull. 1994;33(3):319-23.) via Tyrosine supplementation.
  • Mental performance during fatigue has been shown to improve with increased Tyrosine (Neri DF, Wiegmann D, Stanny RR, Shappell SA, McCardie A, McKay DL. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med. 1995 Apr;66(4):313-9.) supplementation.
  • the diet supplement may include N-acetyl tyrosine.
  • a serving of the diet supplement may include from about 0.1 mg to about 10 mg of N-acetyl tyrosine.
  • the preferred dosage, in a serving of said diet supplement comprises about 1 mg of N-acetyl tyrosine.
  • Gymnema Sylvestre is a plant which is used in traditional Eastern medicine as a treatment for diabetes due to its ability to inhibit glucose absorption in addition to its ability suppress the taste of 'sweetness'.
  • Gymnema extract has been shown to be an effective diabetes treatment in rats (Okabayashi Y, Tani S, Fujisawa T, Koide M, Hasegawa H, Nakamura T, Fujii M, Otsuki M. Effect of Gymnema sylvestre, R.Br, on glucose homeostasis in rats. Diabetes Res Clin Pract. 1990 May-Jun;9(2):143-8.). This is likely due to the ability of Gymnema to suppress glucose absorption in rat intestine (Shimizu K, lino A, Nakajima J, Tanaka K, Nakajyo S, Urakawa N, Atsuchi M, Wada T, Yamashita C.
  • Gymnema has further been shown to be effective in treating diabetes in humans by both lowering blood glucose along with increasing insulin levels (Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol. 1990 Oct;30(3):281-94.; Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER.
  • Gymnema Sylvestre extract can be combined with HCA to produce greater weight loss (Preuss HG, Garis Rl, Bramble JD, Bagchi D, Bagchi M, Rao CV, Satyanarayana S. Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control, lnt J Clin Pharmacol Res. 2005;25(3):133-44.) as experimentally evidenced.
  • the diet supplement may include Gymnema Sylvestre Leaf Extract.
  • a serving of the diet supplement may include from about 1 mg to about 1000 mg of Gymnema Sylvestre Leaf Extract.
  • the preferred dosage, in a serving of said diet supplement comprises about 133 mg of Gymnema Sylvestre Leaf Extract.
  • Withania Somnifera Root Extract Withania Somnifera (Ashwagandha, Winter Cherry) is an herb used in traditional East Indian medicine. Withania Somnifera is reported to have a number of beneficial effects including antioxidant and antistress (Mishra LC 1 Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000 Aug;5(4):334-46) activities. It is also considered to be an adaptogen and therefore, may possess non-specific protective effects, wherein this has been demonstrated in animal studies (Dhuley JN. Adaptogenic and cardioprotective action of ashwagandha in rats and frogs. J Ethnopharmacol.
  • Withania Somnifera has a positive effect on mood by reducing stress and anxiety (Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine. 2000 Dec;7(6):463-9.).
  • Withania Somnifera has been shown to attenuate both age-associated and chemical-induced cellular and tissue oxidative damage in rats (Gupta SK, Dua A, Vohra BP.
  • Withania somnifera Attenuates antioxidant defense in aged spinal cord and inhibits copper induced lipid peroxidation and protein oxidative modifications. Drug Metabol Drug Interact. 2003;19(3):211-22.).
  • the diet supplement may include Withania Somnifera Root Extract.
  • a serving of the diet supplement may include from about 0.1 mg to about 10 mg of Withania Somnifera Root Extract.
  • the preferred dosage, in a serving of said diet supplement comprises about 1 mg of Withania Somnifera Root Extract.
  • Hydroxycitric acid is extracted from the fruit of the Garcinia Cambogia plant. It has been shown to inhibit fat production and suppress appetite and as such is used to control weight by virtue of these characteristics.
  • U.S. Patent No. 6,875,891 entitled “Process for Preparing Highly Water Soluble Double Salts of Hydroxycitric Acid Particularly Alkali and Alkaline Earth Metal Double Salts” describes a method for producing highly water-soluble Calcium and Potassium Hydroxycitric Acid salts which are odorless and essentially tasteless.
  • the process involves the steps of precipitating sparingly soluble alkaline earth metal salts of Hydroxycitric acid from an aqueous extract of plants belonging to the Garcinia species, dissolving said alkaline earth metal salts in aqueous alkali and adjusting the pH of said alkaline solution by adding an extract of purified Garcinia fruit extract. From this process, the Calcium salt of Hydroxycitric Acid can be precipitated. Additionally, said Calcium salt can be treated with Potassium Hydroxide to form the Potassium and Calcium double salt of Hydroxycitric Acid which can further be purified by treatment with activated charcoal, filtered and spray dried.
  • HCA has been shown to inhibit fatty acid synthesis and repress appetite in rats (Watson JA, Fang M, Lowenstein JM. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch Biochem Biophys. 1969 Dec;135(1 ):209-17.; Louter-van de Haar J, Wielinga PY, Scheurink AJ, Nieuwenhuizen AG. Comparison of the effects of three different (-)-hydroxycitric acid preparations on food intake in rats. Nutr Metab (Lond).
  • Garcinia Cambogia extract can also improve glucose metabolism in mice (Hayamizu K, Hirakawa H, Oikawa D, Nakanishi T, Takagi T, Tachibana T, Furuse M. Effect of Garcinia cambogia extract on serum leptin and insulin in mice. Fitorick. 2003 Apr;74(3):267-73.).
  • HCA has been shown to reduce caloric intake (Westerterp- Plantenga MS, Kovacs EM.
  • the diet supplement may include the Calcium and Potassium double salt of Garcinia Cambogia Extract standardized to about 60% Hydroxycitric Acid.
  • a serving of the diet supplement may include from about 100 mg to about 5 g of the Calcium and Potassium double salt of Garcinia Cambogia Extract standardized to about 60% Hydroxycitric Acid.
  • the preferred dosage, in a serving of the diet supplement comprises about 1.555 g of the Calcium and Potassium double salt of Garcinia Cambogia Extract standardized to about 60% Hydroxycitric Acid.
  • Rhodiola Rosea is also known as 'Golden root', 'Arctic root' and Crenulin. Typically, it is considered to be an 'adaptogen' due to the observed ability of Rhodiola to confer increased resistance to multiple stresses, both mental and physical (Kelly GS. Rhodiola rosea: a possible plant adaptogen. Altern Med Rev. 2001 Jun;6(3):293-302.).
  • the mechanism of action for Rhodiola Rosea appears to be primarily its ability to increase the levels of monamine neurotransmitters such as serotonin, dopamine and norepinephrine (Stancheva SL, Mosharrof A. Effect of the extract of Rhodiola rosea L. on the content of the brain biogenic monamines.
  • Rhodiola possesses both cardioprotective (Lishmanov IuB, Maslova LV, Maslov LN, Dan'shina EN. [The anti-arrhythmia effect of Rhodiola rosea and its possible mechanism] Biull Eksp Biol Med. 1993 Aug; 116(8): 175-6.) and anticancer properties (Udintsev SN, Shakhov VP. The role of humoral factors of regenerating liver in the development of experimental tumors and the effect of Rhodiola rosea extract on this process. Neoplasma 1991 ; 38(3):323-331.).
  • Rhodiola extract has marked protective and antioxidant activity (De Sanctis R, De Bellis R, Scesa C, Mancini U, Cucchiarini L, Dacha M. In vitro protective effect of Rhodiola rosea extract against hypochlorous acid-induced oxidative damage in human erythrocytes. Biofactors. 2004;20(3):147-59.).
  • Rhodiola has been shown to improve mental performance (Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue-a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty.
  • Rhodiola can also improve endurance exercise performance (De Bock K, Eijnde BO, Ramaekers M, Hespel P. Acute Rhodiola rosea intake can improve endurance exercise performance, lnt J Sport Nutr Exerc Metab. 2004 Jun;14(3):298-307.).
  • the diet supplement may include Rhodiola Rosea Leaf Extract.
  • a serving of the diet supplement may include from about 1 mg to about 1 g of Rhodiola Rosea Leaf Extract.
  • the preferred dosage, in a serving of said diet supplement comprises about 124 mg of Rhodiola Rosea Leaf Extract.
  • the diet supplement according to this invention provides a method for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, and supporting mental well-being.
  • consumption of the diet supplement is combined with a reduced calorie diet and a program of regular exercise.
  • the diet supplement may be consumed in any form.
  • the dosage form of the diet supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a tablet, a caplet, or as a dietary gel.
  • the most preferred dosage form is a caplet.
  • the diet supplement is consumed by an individual in accordance with the following method:
  • 2 caplets may be taken with an 8 oz. glass of water three times daily.
  • each serving, comprised of 2 caplets may be consumed approximately 30 to 60 minutes before each meal, e.g., breakfast, lunch and dinner.
  • the diet supplement may cause rapid weight loss, control appetite, manage stress, support relaxation, combat fatigue and support mental well-being for an extended period of time, e.g., all day.
  • the dosage form of the diet supplement may be provided in accordance with customary processing techniques for herbal and dietary supplements in any of the forms mentioned above.
  • the diet supplement set forth in the example embodiments herein may contain any appropriate number and type of excipients, as is well known in the art.
  • the present invention relates to a method of manufacturing a diet supplement for causing rapid weight loss, controlling appetite, and managing stress, supporting relaxation, combating fatigue and supporting mental well-being.
  • the method of manufacturing a diet supplement may include the step of mixing one or more of the Calcium and Potassium double salt of Garcinia Cambogia Extract supplying 60% Hydroxycitric Acid, Gymnema Sylvestre Leaf Extract, Rhodiola Rosea Root Extract, Theanine (gamma-glutamylethylamide), Astaxanthin, Chromium Polynicotinate, Hoodia Gordonii (e.g., an extract that does not contain any extract from the root of the plant), N-olyl-phosphatidyl ethanolamine (NOPE)/EGCG blend, Vinpocetine, Russian Tarragon Extract (Artemisia dracunculus L.
  • the Calcium and Potassium double salt of Garcinia Cambogia Extract supplying 60% Hydroxycitric Acid, Gymnema Sylvestre Leaf Extract, Rhodiola Rosea Root Extract,
  • the method of manufacturing the diet supplement may also include the step of checking for uniformity/homogeneity.
  • the method of manufacturing the diet supplement may include the step of aliquoting the mixture into a serving, e.g., for compression into a caplet.
  • a diet supplement for promoting rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being comprising the Calcium and Potassium double salt of Garcinia Cambogia Extract standardized to about 60% Hydroxycitric Acid (1.55500 g), Gymnema Sylvestre Leaf Extract (0.133000 g) standardized to 25% Gymnemic Acids, Rhodiola Rosea Root Extract (0.124000 g) standardized to 3% Rosavins, Theanine (0.052000 g), Astaxanthin Algae Extract (0.00500 g),Chromium Polynicotinate (0.000133 g), Hoodii Gordonii (0.020000 g) plant without the roots, N-olyl-phosphatidyl ethanolamine (NOPE)/EGCG blend (0.00100 g) standardized to 23% NOPE, 20% Polyphenols, 14% EGCG, Vinpocetine (0.00100 g), Russian Tarragon Extract (0.00100 g), N-acetyl tyrosine (
  • each two caplet serving may be consumed approximately 30 to 60 minutes before each meal, e.g., breakfast, lunch and dinner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’invention concerne des compositions et des méthodes pour fournir à l'alimentation d’humains une composition permettant d’induire perte rapide de poids, contrôle de l’appétit, facilitation de la relaxation, lutte contre la fatigue et aide au bien-être mental. Ce supplément alimentaire contient du sel double de calcium et potassium d’extrait de Garcinia Cambogia qui procure 60 % d’acide hydroxycitrique, de l’extrait de feuille de Gymnéma Sylvestre, de l’extrait de racine de Rhodiola Rosea, de la théanine, de l’extrait d’algue astaxanthine, du polynicotinate de chrome, du Hoodia Gordonii, un mélange de N-olyl-phosphatidyle éthanolamine (NOPE)/EGCG, de la vinpocétine, de l’extrait d'estragon de russie, de la N-acétyl tyrosine et de l’extrait de racine de Withania Somnifera. Ledit supplément alimentaire comprend au moins de l’Hoodia gordonii dont l'extrait ne contient aucun extrait de racine de la plante.
PCT/CA2006/000964 2005-06-17 2006-06-13 Supplément alimentaire pour causer perte rapide de poids, contrôle de l’appétit, gestion du stress, facilitation de la relaxation, lutte contre la fatigue et aide au bien-être mental Ceased WO2006133549A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06752797A EP1893225A4 (fr) 2005-06-17 2006-06-13 Supplément alimentaire pour causer perte rapide de poids, contrôle de l appétit, gestion du stress, facilitation de la relaxation, lutte contre la fatigue et aide au bien-être mental
AU2006257660A AU2006257660A1 (en) 2005-06-17 2006-06-13 Diet supplement comprising Hoodia Gordonii for weight loss and mental well-being

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69194505P 2005-06-17 2005-06-17
US60/691,945 2005-06-17

Publications (1)

Publication Number Publication Date
WO2006133549A1 true WO2006133549A1 (fr) 2006-12-21

Family

ID=37531915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/000964 Ceased WO2006133549A1 (fr) 2005-06-17 2006-06-13 Supplément alimentaire pour causer perte rapide de poids, contrôle de l’appétit, gestion du stress, facilitation de la relaxation, lutte contre la fatigue et aide au bien-être mental

Country Status (6)

Country Link
US (2) US20060286183A1 (fr)
EP (1) EP1893225A4 (fr)
AU (1) AU2006257660A1 (fr)
CA (1) CA2550272A1 (fr)
WO (1) WO2006133549A1 (fr)
ZA (1) ZA200709850B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056549A1 (fr) * 2009-10-27 2011-05-12 Access Business Group International Llc Cibles moléculaires et modulateurs alimentaires de lésion musculaire induite par un exercice
DE102009060816A1 (de) * 2009-12-28 2011-06-30 Dr. Loges + Co. GmbH, 21423 Rhodioapräparat mit Zusätzen
ES2386858A1 (es) * 2011-02-07 2012-09-03 Eduardo Antonio Gómez De Diego Composición adelgazante natural.
CN102972776A (zh) * 2012-12-05 2013-03-20 溧阳维信生物科技有限公司 含有三氯蔗糖的中药保健品及其制备方法
RU2484840C2 (ru) * 2007-06-05 2013-06-20 Медести Ресерч Энд Продакшн С.П.А. Композиция для подавления аппетита, улучшения тонуса и настроения с природной антидепрессантной активностью и с антиастеническим действием
CN108410939A (zh) * 2018-07-12 2018-08-17 烟台大学 一种提高雨生红球藻中虾青素含量的方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719542D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Use of cocoa extract
GB0719545D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Novel use of cocoa extract
GB0719544D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
WO2009053980A2 (fr) * 2007-10-24 2009-04-30 Arava Hoodia Growers A. C. S. Ltd. Coupe-faim amélioré
WO2010039676A1 (fr) * 2008-10-02 2010-04-08 Georgetown University Procédés de traitement d'un stress thermique et compositions associées
US8455024B2 (en) * 2008-10-16 2013-06-04 Visalus Holdings, Llc Appetite suppressant composition
US20100124578A1 (en) * 2008-11-17 2010-05-20 Heuer Marvin A Appetite-suppressing weight management composition
US9345732B2 (en) * 2009-11-19 2016-05-24 Laila Nutraceuticals Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
US20120015021A1 (en) * 2010-07-13 2012-01-19 Axiomedic Ltd. Anti-appetite adhesive compositions
ITMI20121822A1 (it) * 2012-10-26 2014-04-27 Felice Marcoccia Composizione dimagrante a base proteica
KR102255235B1 (ko) 2014-04-28 2021-05-21 삼성전자주식회사 알칼리금속 복염을 포함하는 이산화탄소 흡착제 및 그 제조 방법
US10610556B2 (en) 2015-09-17 2020-04-07 Therapeutic Solutions LLC Compositions for regulation and control of appetite
CN106138159A (zh) * 2016-08-05 2016-11-23 四川吉晟生物医药有限公司 一种预防和治疗缺氧引起的失眠的药物组合物
US12433894B2 (en) 2019-06-14 2025-10-07 All Labs, Inc. Stimulant composition and process for making same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047661A2 (fr) * 2000-12-27 2004-06-10 Arthur Zuckerman Dentifrice coupe-faim
US6875891B2 (en) * 2003-05-12 2005-04-05 Laila Impex Process for preparing highly water soluble double salts of hydroxycitric acid particularly alkali and alkaline earth metal double salts

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US20040082657A1 (en) * 2002-10-24 2004-04-29 Peter Spiegel Composition for suppressing the appetite of a human being comprising L-theanine and method of administering same
US7202222B2 (en) * 2003-01-06 2007-04-10 National Bioscience Corporation Methods for treatment of obesity and effective fat loss promotion
WO2005099737A1 (fr) * 2004-04-07 2005-10-27 Rutgers, The State University Of New Jersey Compositions et méthodes coupe-faim
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060263475A1 (en) * 2004-08-25 2006-11-23 Cadbury Adams Usa, Llc. Center-filled chewing gum composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047661A2 (fr) * 2000-12-27 2004-06-10 Arthur Zuckerman Dentifrice coupe-faim
US6875891B2 (en) * 2003-05-12 2005-04-05 Laila Impex Process for preparing highly water soluble double salts of hydroxycitric acid particularly alkali and alkaline earth metal double salts

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BANDERET L.E. AND LEIBERMAN H.R.: "Treatment with Tyrosine, a Neurotransmitter Precursor, Reduces Environmental Stress in Humans", BRAIN RESEARCH BULLETIN, vol. 22, 1989, pages 759 - 762, XP003005559 *
DE BOCK K. ET AL.: "Acute Rhodiola Rosea Intake Can Improve Endurance Exercise Performance", INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM, vol. 14, 2004, pages 298 - 307, XP008074101 *
KAO Y.-H. ET AL.: "Modulation of Endocrine Systems and Food Intake by Green Tea Epigallocatechin Gallate", ENDOCRINOLOGY, vol. 141, no. 3, 2000, pages 980 - 987, XP001154723 *
MISHRA L.-C. ET AL.: "Scientific Basis for the Therapeutic Use of Withania somnifera (Ashwagandha): A Review", ALTERNATIVE MEDICINE REVIEW, vol. 5, no. 4, 2000, pages 334 - 346, XP002216001 *
RIBNICKY D.M. ET AL.: "Toxicological evaluation of the ethanolic extract of Artemisia dracunculus L. for use as a dietary supplement and in functional foods", FOOD AND CHEMICAL TOXICOLOGY, vol. 42, 2004, pages 585 - 598, XP003005558 *
RODRIGUEZ DE FONESCA F. ET AL.: "An anorexic lipid mediator regulated by feeding", NATURE, vol. 414, 8 November 2001 (2001-11-08), pages 209 - 212, XP002245166 *
See also references of EP1893225A4 *
SPILLER G.A. ET AL.: "Safety of an Astaxanthin-Rich Haematococcus pluvilais Algal Extract: A Randomized Clinical Trial", JOURNAL OF MEDICINAL FOOD, vol. 6, no. 1, 2003, pages 51 - 56, XP008074102 *
SUBHAN Z. AND HINDMARCH I.: "Psychopharmacological Effects of Vinpocetine in Normal Healthy Volunteers", EUR J CLIN PHARMACOL, vol. 28, 1985, pages 567 - 571, XP008074117 *
TULP O.L. ET AL.: "Effect of Hoodia Plant on Weight Loss in Congenic Obese La/Ntul/-cp Rats", FASEB J., vol. 16, no. 4, 20 March 2000 (2000-03-20), pages A648, XP008074118 *
WOODGATE D.E. ET AL.: "Double-blind Study Evaluating the Effects of a Novel Herbal Supplement on Weight Loss in Overweight Adults", FASEB J, vol. 15, no. 4, 7 March 2001 (2001-03-07), pages A302, XP009054961 *
ZHENG G. ET AL.: "Anti-obesity Effects of Three Major Components of Green Tea, Catechins, Caffeine and Theanine, in Mice", IN VIVO, vol. 18, no. 1, 2004, pages 55 - 62, XP009060486 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2484840C2 (ru) * 2007-06-05 2013-06-20 Медести Ресерч Энд Продакшн С.П.А. Композиция для подавления аппетита, улучшения тонуса и настроения с природной антидепрессантной активностью и с антиастеническим действием
WO2011056549A1 (fr) * 2009-10-27 2011-05-12 Access Business Group International Llc Cibles moléculaires et modulateurs alimentaires de lésion musculaire induite par un exercice
DE102009060816A1 (de) * 2009-12-28 2011-06-30 Dr. Loges + Co. GmbH, 21423 Rhodioapräparat mit Zusätzen
EP2364715A1 (fr) * 2009-12-28 2011-09-14 Dr. Loges + Co. GmbH Préparation de rhodiol dotée de l'astaxanthine et des vitamines
DE102009060816A8 (de) * 2009-12-28 2011-11-10 Dr. Loges + Co. Gmbh Rhodiolapräparat mit Zusätzen
ES2386858A1 (es) * 2011-02-07 2012-09-03 Eduardo Antonio Gómez De Diego Composición adelgazante natural.
CN102972776A (zh) * 2012-12-05 2013-03-20 溧阳维信生物科技有限公司 含有三氯蔗糖的中药保健品及其制备方法
CN108410939A (zh) * 2018-07-12 2018-08-17 烟台大学 一种提高雨生红球藻中虾青素含量的方法

Also Published As

Publication number Publication date
US20070237786A1 (en) 2007-10-11
ZA200709850B (en) 2009-06-24
EP1893225A1 (fr) 2008-03-05
CA2550272A1 (fr) 2006-12-17
AU2006257660A1 (en) 2006-12-21
US20060286183A1 (en) 2006-12-21
EP1893225A4 (fr) 2009-08-12

Similar Documents

Publication Publication Date Title
US20070237786A1 (en) Diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being.
Zhou et al. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease
JP3953513B2 (ja) ピペリン含有組成物
Downs et al. Bioefficacy of a novel calcium–potassium salt of (−)-hydroxycitric acid
CN112118855A (zh) 体重管理组合物
WO2009094177A1 (fr) Compositions de ginsénoside de type protopanaxadiol et leurs utilisations
MX2010009015A (es) Extracto de hojas de especie panax, proceso para hacer el mismo y usos del mismo.
Manik et al. Anti-diabetic and antihyperlipidemic effect of allopolyherbal formulation in OGTT and STZ-induced diabetic rat model
US20110123654A1 (en) Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon
WO2015198346A1 (fr) Composition comprenant un extrait d'alangium salvifolium à activité anti-adipogène ou anti-obésité
CA3226805A1 (fr) Compositions de substitution de cafeine a base de paraxanthine et methode associee d'utilisation chez des sujets a metabolisme cafeique lent
EP4319759A1 (fr) Composition bioactive à base de 1-méthylxanthine et son procédé d'utilisation
Bawono et al. The role of catechins of Camellia sinensis leaves in modulating antioxidant enzymes: A review and case study
US20060286181A1 (en) Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism
Barron et al. Natural products and the athlete: facts and folklore
CN115813970B (zh) 一种稳定释放的营养靶向组合物及其用途
Yang et al. Red mulberry fruit aqueous extract and silk proteins accelerate acute ethanol metabolism and promote the anti‑oxidant enzyme systems in rats
CN117915902A (zh) 营养组合物
Gencoglu et al. Phytochemical therapies in vascular functioning: a molecular approach
WO2023091127A1 (fr) Complexes de principes actifs, compositions et procédés pour soulager la gueule de bois et atténuer les lésions hépatiques induites par l'alcool
US10610556B2 (en) Compositions for regulation and control of appetite
Deuster et al. Dietary supplements and military divers: A synopsis for undersea medical officers
Algantri et al. Neuroprotective Agents: Implications for Parkinson's Disease Treatment
US20060105965A1 (en) Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations
KR101342489B1 (ko) 씀바귀 잎 추출물을 함유하는 간보호용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006257660

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006752797

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006257660

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 268/CHENP/2008

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2006752797

Country of ref document: EP